Stoke Therapeutics (NASDAQ:STOK) Director Sells $199,204.11 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 6,453 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $30.87, for a total transaction of $199,204.11. Following the completion of the transaction, the director owned 71,102 shares of the company’s stock, valued at approximately $2,194,918.74. This trade represents a 8.32% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Stoke Therapeutics Stock Performance

Shares of STOK traded down $0.18 during mid-day trading on Friday, reaching $30.87. 602,753 shares of the company’s stock traded hands, compared to its average volume of 917,923. The business’s 50-day moving average price is $28.90 and its 200-day moving average price is $19.69. The stock has a market capitalization of $1.76 billion, a P/E ratio of 46.07 and a beta of 1.14. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The business had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. Equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of STOK. CANADA LIFE ASSURANCE Co grew its holdings in shares of Stoke Therapeutics by 12.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company’s stock worth $296,000 after acquiring an additional 1,313 shares during the last quarter. Polar Capital Holdings Plc boosted its position in shares of Stoke Therapeutics by 49.8% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock valued at $31,102,000 after purchasing an additional 439,824 shares during the period. Parkman Healthcare Partners LLC purchased a new position in Stoke Therapeutics in the 3rd quarter worth about $5,875,000. Nomura Holdings Inc. purchased a new position in Stoke Therapeutics in the 3rd quarter worth about $1,908,000. Finally, Millennium Management LLC raised its holdings in Stoke Therapeutics by 199.3% during the 3rd quarter. Millennium Management LLC now owns 61,048 shares of the company’s stock worth $1,435,000 after buying an additional 40,652 shares during the period.

Analyst Upgrades and Downgrades

STOK has been the topic of a number of recent analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Stoke Therapeutics in a research note on Monday. Wedbush boosted their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. increased their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Monday, November 3rd. BTIG Research reiterated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Finally, Needham & Company LLC boosted their target price on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Stoke Therapeutics has an average rating of “Buy” and a consensus price target of $31.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.